VivoSeq
Other

APL

0

Pipeline Programs↗

6

Active Trials↗

2

Companies Involved↗

APL is an early-stage landscape with 0 programs across 2 companies. The most active players are GSK, Ablynx, a Sanofi company.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

84/100

Attrition Rate

12/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

GSK logo

GSK

0 programs

PreclinicalA

Ablynx, a Sanofi company

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

33

clinical trials

Completed21 · 64%
Recruiting5 · 15%
Terminated3 · 9%
Unknown status2 · 6%
Active, not recruiting1 · 3%
Withdrawn1 · 3%

Clinical Trials

Trial Activity

33 trials

Implantation Of Vaginal Construct For Patients With Vaginal Aplasia
Recruiting·WWake Forest University Health Sciences·Phase 1·NCT05675722·10 enrolled
REVerse Intestinal Metaplasia in the Stomach (REVISE)
Recruiting·—·Phase 2·NCT06590454·32 enrolled
Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood
Recruiting·—·Phase 2·NCT06904482·36 enrolled
IS-free Treg HaploHCT
Recruiting·—·Phase 1·NCT04678401·30 enrolled
CD45RA Depleted DLI After TCRα/β Depleted Haploidentical HCT
Recruiting·UUniversity Hospital Tuebingen·Phase 1/2·NCT05943067·60 enrolled
Reversal of Preneoplastic Metaplasia in the Stomach With MEK Inhibitor
Active, not recruiting·VVanderbilt-Ingram Cancer Center·Phase 1·NCT04454476·15 enrolled
A Study to Compare the Bioavailability of 300 mg Trazodone Hydrochloride Extended-release Caplets and 100 mg Trazodone Hydrochloride Immediate-release Tablets at Steady State
Completed·LLabopharm Inc.·Phase 1·NCT01121926·30 enrolled
Intrapleural Fibrinolytic Therapy to Enhance Chemical Pleurodesis Enhance Chemical Pleurodesis
Completed·MMemorial Healthcare System·Phase 4·NCT04806373·27 enrolled
Bioequivalence of Liquid and Reconstituted Lyophilized Subcutaneous Formulations of Caplacizumab.
Completed·AAblynx, a Sanofi company·Phase 1·NCT02189733·24 enrolled
A Study With Darapladib to Collect Tolerability Information
Completed·GSK logoGSK·Phase 1·NCT00704431·2 enrolled
Darapladib China PK
Completed·GSK logoGSK·Phase 1·NCT02000804·24 enrolled
24hr Effects of Tiotropium Bromide in Tetraplegia
Completed·JJames J. Peters Veterans Affairs Medical Center·Phase 2·NCT02586649·10 enrolled
Phase I Study of SB-480848(Darapladib) -Repeat Dose Study in Healthy Japanese Male Subjects-
Completed·GSK logoGSK·Phase 1·NCT00622830·18 enrolled
Study to Evaluate Darapladib in Moderately Hepatically Impaired Subjects
Completed·GSK logoGSK·Phase 1·NCT01154114·24 enrolled
A Study to Compare the Bioavailability of 300 mg Trazodone Hydrochloride Extended-release Caplets and 100 mg Trazodone Hydrochloride Immediate-release Tablets (Administered Three Times Daily)
Completed·LLabopharm Inc.·Phase 1·NCT01121900·26 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)